In this executive summary, we describe formulation and manufacturing considerations for development of dry-powder therapeutics for local treatment of lung cancer. A case study is presented in which an approved drug—topotecan—is successfully formulated for DPI administration to the lung.  
Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center